Geode Capital Management LLC Purchases 277,001 Shares of Guardant Health, Inc. $GH

Geode Capital Management LLC lifted its position in Guardant Health, Inc. (NASDAQ:GH) by 9.4% in the fourth quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 3,213,657 shares of the company’s stock after buying an additional 277,001 shares during the period. Geode Capital Management LLC owned about 2.55% of Guardant Health worth $328,297,000 as of its most recent SEC filing.

A number of other large investors have also made changes to their positions in GH. V Square Quantitative Management LLC bought a new stake in shares of Guardant Health in the 4th quarter valued at $27,000. Chesapeake Asset Management LLC bought a new stake in shares of Guardant Health in the 4th quarter valued at $28,000. Thurston Springer Miller Herd & Titak Inc. bought a new stake in shares of Guardant Health in the 4th quarter valued at $31,000. Elyxium Wealth LLC bought a new stake in shares of Guardant Health in the 4th quarter valued at $35,000. Finally, First Pacific Financial bought a new stake in shares of Guardant Health in the 4th quarter valued at $43,000. Institutional investors own 92.60% of the company’s stock.

Guardant Health Price Performance

Shares of NASDAQ GH opened at $129.14 on Tuesday. The stock has a market capitalization of $17.12 billion, a price-to-earnings ratio of -38.09 and a beta of 1.61. The business has a 50-day moving average of $95.88 and a 200-day moving average of $100.18. Guardant Health, Inc. has a fifty-two week low of $39.69 and a fifty-two week high of $133.97.

Wall Street Analysts Forecast Growth

GH has been the subject of a number of research reports. Weiss Ratings reiterated a “sell (d-)” rating on shares of Guardant Health in a report on Tuesday, April 21st. BTIG Research set a $160.00 target price on Guardant Health and gave the stock a “buy” rating in a report on Wednesday, May 27th. Piper Sandler set a $127.00 target price on Guardant Health in a report on Thursday, May 21st. TD Cowen reiterated a “buy” rating on shares of Guardant Health in a report on Thursday, May 21st. Finally, Raymond James Financial reiterated an “outperform” rating and set a $129.00 target price on shares of Guardant Health in a report on Monday, February 23rd. Nineteen investment analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat, Guardant Health presently has a consensus rating of “Moderate Buy” and a consensus price target of $129.79.

Insiders Place Their Bets

In related news, Director Medina Manuel Hidalgo sold 1,000 shares of the firm’s stock in a transaction dated Thursday, May 28th. The shares were sold at an average price of $130.06, for a total value of $130,060.00. Following the completion of the sale, the director directly owned 639 shares in the company, valued at approximately $83,108.34. This trade represents a 61.01% decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, CEO Amirali Talasaz sold 210,000 shares of the firm’s stock in a transaction dated Wednesday, May 20th. The shares were sold at an average price of $109.89, for a total transaction of $23,076,900.00. Following the completion of the sale, the chief executive officer owned 1,886,504 shares of the company’s stock, valued at $207,307,924.56. This trade represents a 10.02% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold a total of 332,244 shares of company stock worth $36,156,026 in the last three months. Insiders own 5.60% of the company’s stock.

Guardant Health Profile

Guardant Health, Inc is a precision oncology company specializing in blood-based cancer diagnostics. Founded in 2012 and headquartered in Redwood City, California, the company develops non-invasive tests that use circulating tumor DNA (ctDNA) to profile genomic alterations in patients with solid tumors. Guardant Health’s mission is to advance cancer care by providing actionable data to clinicians, pharmaceutical partners and researchers worldwide.

The company’s flagship product, Guardant360, is a next-generation sequencing (NGS) assay designed to detect mutations, copy number variations and select fusions in more than 70 cancer-related genes.